Iron chelator - DOR BioPharma/Elan/Schein

Drug Profile

Iron chelator - DOR BioPharma/Elan/Schein

Latest Information Update: 28 Aug 2007

Price : $50

At a glance

  • Originator DOR BioPharma; Elan Corporation
  • Class
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Iron overload

Most Recent Events

  • 10 Dec 2001 Endorex Corporation is now called DOR BioPharma
  • 25 Feb 2000 Preclinical development for Iron overload in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top